Efficacy of IP-10 as a biomarker for monitoring tuberculosis treatment - 15/02/14

Doi : 10.1016/j.jinf.2013.09.033

Ji Young Hong ^a, Hye Jon Lee ^b, Song Yee Kim ^a, Kyung Soo Chung ^a, Eun Young Kim ^a, Ji Ye Jung ^a, Moo Suk Park ^a, Young Sam Kim ^a, Se Kyu Kim ^a, Joon Chang ^a, Sang-Nae Cho ^b, Young Ae Kang ^a,^⁎
^a Division of Pulmonology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
^b Department of Microbiology, Yonsei University College of Medicine, Seoul, Republic of Korea

^∗Corresponding author. Division of Pulmonology, Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonseiro, Seodaemun-gu, Seoul 120-752, Republic of Korea. Tel.: +82 2 2228 1986; fax: +82 2 393 6884.

Summary

Objectives

IP-10 has been proposed as a promising alternative marker for the diagnosis of tuberculosis (TB).

Methods

In this exploratory study, we assessed the levels of serum IP-10 and TB antigen-dependent IP-10 at the time of diagnosis and after completing treatment in 32 patients with active TB.

Results

Significant changes in concentration between the time of diagnosis and the completion of therapy were observed for serum IP-10 (P < 0.001; median: 140.4 and 105.7 pg/ml, respectively) and TB antigen-dependent IP-10 (P = 0.002; median: 20,000 and 13,720 pg/ml, respectively). The proportion of TB antigen-dependent IP-10 responders did not change significantly between baseline and the completion of therapy (P = 0.35), whereas the proportion of serum IP-10 responders was significantly different (P = 0.001).

Conclusions

Serum IP-10 and TB antigen-dependent IP-10 responses to QFT-GIT antigens might be a useful biomarker for monitoring the efficacy of therapy in patients with active TB.

Le texte complet de cet article est disponible en PDF.

Keywords : IP-10, Monitoring, Tuberculosis

Plan

Introduction

Methods

Subjects and data collection

Diagnosis and TB treatment

Subjects' characteristics

IP-10 and IFN-γ levels according to the AFB smear grade at diagnosis

Longitudinal analysis of serum IP-10 in patients with active TB who were followed until therapy completion

Longitudinal analysis of IP-10 in response to M. tuberculosis-specific antigens in QFT-GIT assays of patients with active TB who were followed until therapy completion

Longitudinal analysis of IFN-γ in response to M. tuberculosis-specific antigens in QFT-GIT assays of patients with active TB who were followed until therapy completion

Discussion

Ethical approval

Conflicts of interest

Export

Vol 68 - N° 3

P. 252-258 - mars 2014 Retour au numéro

Article précédent

Staphylococcus aureus bloodstream infection: A pooled analysis of five prospective, observational studies
Achim J. Kaasch, Gavin Barlow, Jonathan D. Edgeworth, Vance G. Fowler, Martin Hellmich, Susan Hopkins, Winfried V. Kern, Martin J. Llewelyn, Siegbert Rieg, Jesús Rodriguez-Baño, Matthew Scarborough, Harald Seifert, Alex Soriano, Robert Tilley, M. Estée T?r?k, Verena Weiß, A.Peter R. Wilson, Guy E. Thwaites, ISAC, INSTINCT, SABG, UKCIRG, and Colleagues p

| Article suivant

Multi-drug-resistant tuberculosis in HIV positive patients in Eastern Europe
Frank A. Post, Daniel Grint, Anne Marie Werlinrud, Alexander Panteleev, Vieja Riekstina, Evgeniy A. Malashenkov, Alena Skrahina, Dan Duiculescu, Daria Podlekareva, Igor Karpov, Vasiliy Bondarenko, Nelly Chentsova, Jens Lundgren, Amanda Mocroft, Ole Kirk, Jose M. Miro, HIV-TB Study Group n

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Efficacy of IP-10 as a biomarker for monitoring tuberculosis treatment - 15/02/14

Summary

Objectives

Methods

Results

Conclusions

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL